KDOQI Update 2000
 
NKF KDOQI GUIDELINES 2000
 
 

GUIDELINES FOR ANEMIA OF CHRONIC KIDNEY DISEASE

IX. References

1. Deleted in proof.

2. Deleted in proof.

3. Eschbach JW, Adamson JW: Anemia of end-stage renal disease (ESRD). Kidney Int 28:1-5, 1985 - No Abstract Available

4. Horina JH, Schwaberger G, Brussee H, Sauseng-Fellegger G, Holzer H, Krejs GJ: Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 8:1219-1222, 1993

5. Robertson HT, Haley NR, Guthrie M, Cardenas D, Eschbach JW, Adamson JW: Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 15:325-332, 1990

6. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U: Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 58:129-134, 1991

7. Teehan B, Sigler MH, Brown JM, Benz RL, Gilgore GS, Schleifer CR, Morgan CM, Gabuzda TG, Kelly JJ, Figueroa WG, Peterson DD: Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Transplant Proc 21:63-66, 1989 - No Abstract Available

8. Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H: Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 34:525-528, 1988

9. Wizemann V, Schafer R, Kramer W: Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 64:202-206, 1993

10. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 47:884-890, 1995

11. Wizemann V, Kaufmann J, Kramer W: Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 62:161-165, 1992

12. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Maiorca R: Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 34:272-278, 1990

13. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KAA, Coles GA, Williams JD: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335:489-493, 1990

14. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 35:280-287, 1991

15. Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR: Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 14:478-485, 1989

16. Eschbach JW, Adamson JW: Recombinant human erythropoietin: Implications for nephrology. Am J Kidney Dis 11:203-209, 1988

17. Ramirez G, Bittle PA, Sanders H, Rabb HAA, Bercu BB: The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin. J Clin Endocrinol Metab 78:63-69, 1994

18. Schaefer RM, Kokot F, Heidland A: Impact of recombinant erythropoietin on sexual function in hemodialysis patients. Contrib Nephrol 76:273-282, 1989 - No Abstract Available

19. Sobh MA, Abd el Hamid IA, Atta MG, Refaie AF: Effect of erythropoietin on sexual potency in chronic haemodialysis patients: A preliminary study. Scand J Urol Nephrol 26:181-185, 1992

20. Gafter U, Kalechman Y, Orlin JB, Levi J, Sredni B: Anemia of uremia is associated with reduced in vitro cytokine secretion: Immunopotentiating activity of red blood cells. Kidney Int 45:224-231, 1994

21. Vanholder R, Van Biesen W, Ringoir S: Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 44:208-214, 1993

22. Scigalla P, Bonzel KE, Bulla M, Burghard R, Dippel J, Geisert J, Leumann E, von Lilien T, Muller-Wiefel DE, Offner G, Pistor K, Zoellner K: Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease. Contrib Nephrol 76:227-241, 1989 - No Abstract Available

23. Burke JR: Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Pediatr Nephrol 9:558-561, 1995

24. Evans RW, Rader B, Manninen DL, Cooperative Multicenter EPO Clinical Trial Group: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263:825-830, 1990

25. Lowrie EG, Ling J, Lew NL, Yiu Y: The relative contribution of measured variables to death risk among hemodialysis patients, in Friedman EA (ed): Death on Hemodialysis: Preventable or Inevitable? 13. Boston, MA, Kluwer Academic Publishers, 1994, pp 121-141

26. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35:134-148, 1989 - No Abstract Available

27. Parker PA, Izard MW, Maher JF: Therapy of iron deficiency anemia in patients on maintenance dialysis. Nephron 23:181-186, 1979

28. Potasman I, Better OS: The role of secondary hyperparathyroidism in the anemia of chronic renal failure. Nephron 33:229-231, 1983 - No Abstract Available

29. Adamson JW, Eschbach JW: Management of the anaemia of chronic renal failure with recombinant erythropoietin. Q J Med New Series 73:1093-1101, 1989 - No Abstract Available

30. Kaiser L, Schwartz KA: Aluminum-induced anemia. Am J Kidney Dis 6:348-352, 1985

31. Hampers CL, Streiff R, Nathan DG, Snyder D, Merrill JP: Megaloblastic hematopoiesis in uremia and in patients on long-term hemodialysis. N Engl J Med 276:551-554, 1967 - No Abstract Available

32. Eschbach JW, Funk DD, Adamson J, Kuhn K, Scribner BH, Finch CA: Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 276:653-658, 1967 - No Abstract Available

33. Eschbach JW: The future of r-HuEPO. Nephrol Dial Transplant 10:96-109, 1995 (suppl 2)

34. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2:1175-1178, 1986

35. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987

36. Mocks J, Franke W, Ehmer B, Scigalla P, Quarder O: Analysis of safety database for long-term epoetin-beta treatment. A meta-analysis covering 3697 patients, in Koch KM, Stein G (eds): Pathogenetic and Therapeutic Aspects of Chronic Renal Failure. 12. New York, Marcel Dekker, 1997, pp 163-179

37. Consensus Development Conference Panel: Morbidity and mortality of renal dialysis: An NIH consensus conference statement. Ann Intern Med 121:62-70, 1994 - No Abstract Available

38. Grutzmacher P, Scheuermann E, Low I, Bergmann M, Rauber K, Baum R, Heuser J, Schoeppe W: Correction of renal anaemia by recombinant human erythropoietin: Effects on myocardial function. Contrib Nephrol 66:176-184, 1988 - No Abstract Availalbe

39. Delano BG: Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 14:14-18, 1989

40. Muirhead N, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, Parfrey P: Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 26:S1-S24, 1995 (suppl 1)

41. Henry JB: Methods Hematology: Basic Methodology, in Clinical Diagnosis and Management by Laboratory Methods (ed 19). Philadelphia, PA, Saunders, 1996, pp 578-625

42. Britten GM, Brecher G, Johnson CA, Elashoff RM: Stability of blood in commonly used anticoagulants. Am J Clin Pathol 52:690-694, 1969 - No Abstract Available

43. Holt JT, DeWandler MJ, Aevan DA: Spurious elevation of electronically determined mean corpuscular volume and hematocrit caused by hyperglycemia. Am J Clin Pathol 77:561-567, 1982

44. Van Duijniioven HLP, Treskes M: Marked interference of hyperglycemia in measurements of mean (red) cell volume by Technicon H analyzers. Clin Chem 1:76-80, 1996

45. Paterakis GS, Laoutaris NP, Alexia SV, Siourounis PV, Stamulakatou AK, Premetis EE, Sakollariou CH, Terzoglou GN, Papassotiriou IG, Loukopoulos D: The effect of red cell shape on the measurement of red cell volume. A proposed method for the comparative assessment of this effect among various haematology analysers. Clin Lab Haematol 16:235-245, 1994

46. Fraser CG, Wilkinson SP, Neville RG, Knox JDE, King JF, MacWalters RS: Biologic variation of common hematologic laboratory quantities in the elderly. Am J Clin Pathol 92:465-470, 1989

47. Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN (eds): Wintrobe’s Clinical Hematology. Appendix A (ed 9). Philadelphia, PA, Lea & Febiger, 1993, p 2303

48. Hillman RS, Finch CA: Clinical approach–Anemia, in Hillman RD, Finch CA (eds): Red Cell Manual (ed 5th). Philadelphia, PA, F.A. Davis Company, 1985, p 24

49. Gokal R, Weatherall DJ, Bunch C: Iron induced increase in red cell size in haemodialysis patients. Q J Med 48:393-401, 1979

50. Hutchinson F, Jones WJ: A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. Am J Kidney Dis 29:651-657, 1997

51. Loge JP, Lange RD, Moore CV: Characterization of the anemia associated with chronic renal insufficiency. Am J Med 24:4-18, 1958

52. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996

53. Bainton DF, Finch CA: The diagnosis of iron deficiency anemia. Am J Med 37:62-70, 1964

54. Jacobs A, Worwood M: Ferritin in serum: Clinical and biochemical implications. N Engl J Med 292:951-956, 1975 - No Abstract Available

55. Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. BMJ 304:471-472, 1992 - No Abstract Available

56. Schaefer RM, Schaefer L: The hypochromic red cell: A new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinatol Med 23:83-88, 1995

57. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Wayne Taylor D: Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 43:184-188, 1995

58. Hakim RM, Lazarus JM: Biochemical parameters in chronic renal failure. Am J Kidney Dis 11:238-247, 1988

59. Chandra M, Clemons GK, McVicar MI: Relation of serum erythropoietin levels to renal excretory function: Evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr 113:1015-1021, 1988

60. McGonigle RJS, Boineau FG, Beckman B, Ohene-Frempong K, Lewy JE, Shadduck RK: Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease. J Lab Clin Med 105:449-458, 1985

61. Schilling RF: Anemia of chronic disease: A misnomer. Ann Intern Med 115:572-573, 1991- No Abstract Available

62. Krantz SB: Pathogenesis and treatment of anemia of chronic disease. Am J Med Sci 307:353-359, 1994

63. Pereira BJG: Balance between pro-inflammantory cytokines and their specific inhibitors in patients on dialysis. Nephrol Dial Transplant Suppl 10:27-32, 1995 - No Abstract Available

64. Eschbach JW, Haley NR, Egrie JC, Adamson JW: A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 42:407-416, 1992

65. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson J: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989

66. US Renal Data System: The USRDS Dialysis Morbidity and Mortality Study (Wave 1). in National Institutes of Health, National Institute Diabetes and Digestive and Kidney Diseases (eds): US Renal Data System 1996 Annual Data Report. Bethesda, MD, 1996, pp 45-67

67. Wolfe R, Port F, Wess R, Bloembergen W, Hirth R, Young E, Ojo A, Strawderman R, Parekh R, Stack A, Tedeschi P, Hulbert-Shearon T, Ashby V, Callard S, Hanson J, Jain A, Meyers-Purkiss A, Roys E, Brown P, Wheeler J, Jones C, Greer J, Agoda L: Introduction to the Excerpts From the United States Renal Data System 1999 Annual Data Report. Am J Kidney Dis 34:S1-S3, 1999 (suppl) - No Abstract Available

68. Guthrie M, Cardenas D, Eschbach JW, Haley NR, Robertson HT, Evans RW: Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 39:97-102, 1993

69. Fellner SK, Lang RM, Neumann A, Korcarz C, Borow KM: Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 44:1309-1315, 1993

70. Low-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe W: Long-term echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin. Blood Purif 8:272-278, 1990

71. Junor BJR: Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful. Perit Dial Int 13:S535-S537, 1993 - No Abstract Available

72. Shinaberger JH, Miller JH, Gardner PW: Erythropoietin alert: Risks of high hematocrit hemodialysis. ASAIO Trans 34:179-184, 1988

73. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300:573-578, 1990

74. McMahon LP, Johns JA, McKenzie A, Austin M, Fowler R, Dawborn JK: Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 7:1199-1206, 1992

75. McMahon LP, Dawborn JK: Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 12:162-169, 1992

76. Sangkabutra T, McKenna MJ, Mason K, Crankshaw DP, McMahon LP: Effects of K+, pH, and different haemoglobin levels on maximal exercise performanace in haemodialysis patients. Nephrology 2:S304A, 1997 (abstr)

77. Mason K, Skinner S, Sangkabutra T, Burge C, McMahon L: Effects of erythropoietin on cardiac mass and function, ambulatory blood pressure and blood volumes at comparative levels of haemoglobin. Nephrology 2:S304A, 1997 (abstr)

78. Mason K, McMahon LP: Normalization of haemoglobin in haemodialysis patients: A comparative study. Nephrology 2:S305A, 1997 (abstr)

79. McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D: Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 14:1182-1187, 1999

80. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin. N Engl J Med 339:584-590, 1998

81. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61, 1996

82. Ritz E, Zeier M, Schneider P, Jones E: Cardiovascular mortality of patients with polycystic kidney disease on dialysis: Is there a lesson to learn? Nephron 66:125-128, 1994 - No Abstract Available

83. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8:1921-1929, 1997

84. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity–The experience of the Lombardy Dialysis Registry [news]. Nephrol Dial Transplant 13:1642-1644, 1998 - No Abstract Available

85. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999

86. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996

87. Greaves SG, Gamble GD, Collins JF, Whalley GA, Sharpe DN: Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis 24:768-776, 1994

88. London GM, Fabiani F, Marchais SJ, De Vernejoul M, Guerin AP, Safar ME, Metivier F, Llach F: Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int 31:973-980, 1987

89. Silberberg JS, Rahal DP, Patton DR, Sniderman AD: Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 64:222-224, 1989

90. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hyperytrophy on survival in end-stage renal disease. Kidney Int 36:286-290, 1989

91. Silberberg J, Racine N, Barre P, Sniderman AD: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 6:1-4, 1990

92. Nagao K, Tsuchihashi K, Ura N, Nakata T, Shimamoto K: Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Can J Cardiol 13:747-753, 1997

93. Levin NW, Lazarus JM, Nissenson AR: Maximizing patient benefits with epoetin alfa therapy. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure–An interim report. Am J Kidney Dis 22:3-12, 1993

94. Ifudu O, Paul H, Mayers JD, Cohen LS, Brezsnyak WF, Herman AI, Avram MM, Friedman EA: Pervasive failed rehabilitations in center-based maintenance hemodialysis patients. Am J Kidney Dis 23:394-400, 1994

95. Erythropoietin, in Disney APS (ed): Report of the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) (ed 16). Woodville, Adelaide, South Australia, 1993, pp 130-135

96. Auer J, Simon G, Stevens J, Griffiths P, Howarth D, Anastassiades E, Gokal R, Oliver D: Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 12:40-42, 1992

97. Valderrabano F: Erythropoetin in chronic renal failure. Kidney Int 50:1373-1391, 1996 - No Abstract Available

98. Walls J: Haemoglobin–Is more better? Nephrol Dial Transplant 10:56-61, 1995

99. Paganini EP: In search of an optimal hematocrit level in dialysis patients: Rehabilitation and quality-of-life implications. Am J Kidney Dis 24:S10-S16, 1994

100. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554, 1995

101. Brown CD, Friedman EA: Clinical and blood rheologic stability in erythropoietin-treated predialysis patients. Am J Nephrol 10:29-33, 1990

102. Abraham PA, Opsahl JA, Rachael KM, Asinger R, Halstenson CE: Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 10:128-136, 1990

103. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989

104. Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J: Recombinant human erythropoietin treatment in pre-dialysis patients: A double-blind placebo-controlled trial. Ann Intern Med 110:108-114, 1989

105. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI: The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial. Am J Kidney Dis 14:486-495, 1989

106. Koch KM, Koene RAP, Messinger D, Quarder O, Scigalla P: The use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol 44:201-208, 1995

107. Clyne N, Jogestrand T: Effect of erythropoeitin treatment on physical exercise capacity and renal function in predialytic uremic patients. Nephron 60:390-396, 1992

108. Suzuki M, Tsutsui M, Yokoyama A, Hirasawa Y: Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities. Artif Organs 19:1258-1261, 1995

109. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316, 1999

110. Bonelli C, Alvarez S, Alsina M, Brana D: Search of a good hematocrit (H) for patients (P) with a chronic renal insuffiency in hemodialysis. International Congress of Nephrology, Madrid, Spain, July 1995, p 507

111. Eschbach JW, Glenny R, Robertson T, Guthrie M, Rader B, Evans R, Chandler W, Davidson R, Easterling T, Denney J, Schneider G: Normalizing the hematocrit (HCT) in hemodialysis patients (HDP) with EPO improves quality of life (Q/L) and is safe. J Am Soc Nephrol 4:425A, 1993 (abstr)

112. Riedel E, Hampl H, Nundel M, Bosch J: Total correction of renal anemia improves malnutrition and amino acid (AA) metabolism in hemodialysis (HD) patients. J Am Soc Nephrol 7:1462A, 1996 (abstr)

113. Barany P, Svedenhag J, Katzarski K, Divino Filho J, Norman R, Freyschiuss U, Bergstrom J: Physiological effects of correcting anemia in hemodialysis patients to a normal HB. J Am Soc Nephrol 7:1472A, 1996 (abstr)

114. Benz RL, Pressman MR, Hovick ET, Peterson DD: Relationship between anemia of chronic renal failure (ACRF) and sleep, sleep disorders, and daytime alertness: Benefits if normalizing hematocrit (The Sleepo Trial). J Am Soc Nephrol 7:1473A, 1996 (abstr)

115. Mak HK: Human recombinant erythropoietin (EPO) corrects insulin resistance and hyperlipidemia in patients on peritoneal dialysis(PD). J Am Soc Nephrol 7:1490A, 1996 (abstr)

116. Nissenson AR, Pickett JL, Theberge DC, Brown WS, Schweitzer SV: Brain function is better in hemodialysis (HD) patients (PTS) when hematocrit (HCT) is normalized with erythropoeitin (rHuEPO). J Am Soc Nephrol 7:1459A, 1996 (abstr)

117. Avram MM, Sreedhara R, Batish R, Chattopadhyay J, Mittman N: Characteristics of very long-term survivors on hemodialysis (HD); survival up to 30 years. J Am Soc Nephrol 7:1462A, 1996 (abstr)

118. Hayashi T, Shoji T, Okada N, Nakanishi T, Tsubakihara Y: To see the effect on circadian blood pressure variation and cardiac function in predialysis patients when hematocrit is normalized to 40% following recombinant human erythropoietin. Nephrology 2:S304A, 1997 (abstr)

119. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR: Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33:1122-1130, 1999

120. Metry G, Wikstrom B, Valind S, Sandhagen B, Linde T, Beshara S, Langstrom B, Danielson BG: Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol 10:854-863, 1999

121. Benz R, Pressman M, Hovick E, Peterson D: A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients: The SLEEPO Study. Am J Kidney Dis 34:1089-1095, 1999

122. Christopherson R, Frank S, Norris E, Rock P, Gottlieb S, Beattie C: Low postoperative hematocrit is associated with cardiac ischemia in high-risk patients. Anesthesiology 75:99A, 1991 (abstr)

123. Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE: Prognostic determinants in lupus nephritis: A long-term clinicopathologic study. Lupus 4:109-115, 1995

124. Abels RI: Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 19:29-35, 1992

125. Klein L: Premature birth and maternal prenatal anemia. Am J Obstet Gynecol 83:588-590, 1961

126. Wood JH, Kee DB: Hemorrheology of the cerebral circulation in stroke. Stroke 16:765-772, 1985 - No Abstract Available

127. Crowell JW, Smith EE: Determinant of the optimal hematocrit. J Appl Physiol 22:501-504, 1967 - No Abstract Available

128. Kusunoki M, Kimura K, Nakamura M, Isaka Y, Yoneda S, Abe H: Effects of hematocrit variations on cerebral blood flow and oxygen transport on ischemic cerebrovascular disease. J Cerebral Blood Flow Metab 1:413-417, 1981

129. Berns J, Rudnick M, Cohen R, Bower J, Wood B: Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 56:253-260, 1999

130. Iseki K, Nishime K, Uehara H, Tokuyama K, Toma S, Yoshihara K, Kowatari T, Terukina S, Osawa A, Fukiyama K: Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 72:30-36, 1996

131. Charles G, Lundin AP III, Delano BG, Brown C, Friedman EA: Absence of anemia in maintenance hemodialysis. Int J Artif Organs 4:277-279, 1981

132. Council on Food and Nutrition, Committee on Iron Deficiency: Iron deficiency in the United States. JAMA 203:119-124, 1968 - No Abstract Available

133. Muller-Wiefel DE, Sinn H, Gilli G, Scharer K: Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 8:481-486, 1977

134. Allegra V, Mengozzi G, Vasile A: Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 57:175-182, 1991

135. Horl WH, Dreyling K, Steinhauer HB, Engelhardt R, Schollmeyer P: Iron status of dialysis patients under rhuEPO therapy. Contrib Nephrol 87:78-86, 1990 - No Abstract Available

136. Fishbane S, Lynn RI: The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 44:238-240, 1995

137. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK: The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7:2654-2657, 1996

138. Tarng DC, Chen TW, Huang TP: Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15:230-237, 1995

139. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995

140. Silverberg DS, Blum M, Peer G, Kaplan F, Iaina A: Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72:413-417, 1996

141. Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996

142. Granolleras C, Oules R, Branger B, Fourcade J, Shaldon S: Iron supplementation of hemodialysis patients receiving recombinant human erythropoietin therapy, in Bauer C, Koch KM, Scigalla P, Wieczorek L (eds): Erythropoietin: Molecular Physiology and Clinical Applications. New York, NY, Marcel Dekker, 1993, pp 211-218

143. Rosenlof K, Kivivuori SM, Gronhagen-Riska C, Teppo AM, Slimes MA: Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 43:249-255, 1995

144. Taylor JE, Peat N, Porter C, Morgan AG: Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11:1079-1083, 1996

145. Sunder-Plassmann G, Horl WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995

146. Sepandj F, Jindal K, West M, Hirsch D: Economic appraisal of maintenance parenteral iron administration in treatment of the anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:319-322, 1996

147. Fishbane S, Lynn RI: The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 25:426-432, 1995

148. Horl WH: How to get the best out of r-HuEPO. Nephrol Dial Transplant 10:92-95, 1995

149. Bergmann M, Grutzmacher P, Heuser J, Kaltwasser JP: Iron metabolism under rEPO therapy in patients on maintenance hemodialysis. Int J Artif Organs 13:109-112, 1990

150. Wingard RL, Parker RA, Ismail N, Hakim RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25:433-439, 1995

151. Kooistra MP, van Es A, Struyvenberg A, Marx JJM: Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 79:634-639, 1991

152. Dunea G, Swagel MA, Bodiwala U, Arruda JAL: Intradialytic oral iron therapy. Int J Artif Organs 17:261-264, 1994

153. Anastassiades EG, Howarth D, Howarth J, Shanks D, Waters HM, Hyde K, Geary CG, Yin JAL, Gokal R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8:846-853, 1993

154. Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledingham JGG, Oliver DO: Iron metabolism in haemodialysis patients: A study of the management of iron therapy and overload. Q J Med 48:369-391, 1979 - No Abstract Available

155. Eschbach JW, Cook JD, Scribner BH, Finch CA: Iron balance in hemodialysis patients. Ann Intern Med 87:710-713, 1977

156. Milman N: Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol 17:77-81, 1982

157. Donnelly SM, Posen GA, Ali MAM: Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 14:271-276, 1991

158. Eschbach JW, Cook JD, Finch CA: Iron absorption in chronic renal disease. Clin Sci 38:191-196, 1970 - No Abstract Available

159. Hughes RT, Smith T, Hesp R, Hulme B, Dukes DC, Bending MB, Pearson J, Raja KB, Cotes PM, Pippard MJ: Regulation of iron absorption in iron loaded subjects with end stage renal disease: Effects of treatment with recombinant human erythropoietin and reduction of iron stores. Br J Haematol 82:445-454, 1992

160. Skikne BS, Cook JD: Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 120:746-751, 1992

161. Suh H, Wadhwa NK: Iron dextran treatment in peritoneal dialysis patients on erythropoietin. Adv Perit Dial 8:464-466, 1992

162. Senger JM, Weiss RJ: Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J 23:319-323, 1996

163. Schaefer RM, Schaefer L: Management of iron substitution during rHuEPO therapy in chronic renal failure patients. Erythropoiesis 3:71-75, 1992

164. Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34:21-28, 1999

165. Nissenson A, Lindsay R, Swan S, Seligman P, Strobos J: Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 33:471-482, 1999

166. Sunder-Plassmann G, Horl WH: Safety of intravenous injection of iron saccharate in hemodialysis patients. Nephrol Dial Transplant 11:1797-1802, 1996

167. Zanen AL, Adriaansen HJ, van Bommel EFH, Posthuma R, de Jong GMT: Oversaturation of transferin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 11:820-824, 1996

168. Roe DJ, Harford AM, Zager PG, Wiltbank TB, Kirlin L, Della Valle AM, Van Wyck DB: Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents. Am J Kidney Dis 28:855-860, 1996

169. Henderson PA, Hillman RS: Characteristics of iron dextran utilization in man. Blood 34:357-375, 1969 - No Abstract Available

170. Jabs K, Alexander S, McCabe D, Lerner G, Harmon W: Primary results from the U.S. multicenter pediatric recombinant erythropoietin study. J Am Soc Nephrol 5:456A, 1994 (abstr)

171. Horl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-Plassmann G: How to diagnose and correct iron deficiency during r-huEPO therapy–A concensus report. Nephrol Dial Transplant 11:246-250, 1996 - No Abstract Available

172. Navarro JF, Teruel JL, Liano F, Marcen R, Ortuno J: Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol 16:268-272, 1996

173. Rolla G, Bucca C, Brussino L: Systemic reactions to intravenous iron therapy patients receiving angiotensin converting enzyme inhibitor. J Allergy Clin Immunol 93:1074-1075, 1994 - No Abstract Available

174. Nyvad O, Danielsen H, Madsen S: Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet 344:1305-1306, 1994 - No Abstract Available

175. Pascual J, Teruel JL, Liano F, Sureda A, Ortuno J: Serious adverse reactions after intravenous ferric gluconate. Nephrol Dial Transplant 7:271-272, 1992 - No Abstract Available

176. Hamstra RD, Block MH, Schocket A: Intravenous iron dextran in clinical medicine. JAMA 243:1726-1731, 1980

177. Stivelman JC: Optimization of iron therapy in hemodialysis patients treated with rHuEPO. Semin Dial 7:288-292, 1994

178. St. Peter WL, Lambrecht LJ, Macres M: Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28:523-528, 1996

179. Seligman, PA, Schleicher RB: Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 45: 898-901, 1999 - No Abstract Available

180. Faich G, Strobos J: Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 33:464-470, 1999

181. Fishbane S, Ungureanu V, Maesaka JK, Kaupke CJ, Lim V, Wish J: Safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534, 1996

182. Lawrence R: Development and comparison of iron dextran products. PDA J Phar Sci Technol 52:190-197, 1998

183. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26:292-299, 1995

184. Auerbach M, Chaudhry M, Goldman H, Ballard H: Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial. J Lab Clin Med 131:257-260, 1999

185. Auerbach M, Winchester J, Wahab A, Richards K, McGinley M, Hall F, Anderson J, Briefel G: A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 31:81-86, 1998

186. Ahsan N: Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single center comparative study. J Am Soc Nephrol 664-668, 1998

187. Ali M, Fayemi AO, Rigolosi R, Frascino J, Marsden JT, Malcom D: Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA 244:343-345, 1980

188. Bregman H, Gelfand MC, Winchester JF, Manz HJ, Knepshield JH, Schreiner GE: Iron-overload-associated myopathy in patients on maintenance haemodialysis: A histocompatibility-linked disorder. Lancet 2:882-885, 1980

189. Hakim RM, Stivelman JC, Schulman G, Fosburg M, Wolfe L, Imber MJ, Lazarus JM: Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 10:293-299, 1987

190. Stivelman J, Schulman G, Fosburg M, Lazarus JM, Hakim RM: Kinetics and effficacy of deferoxamine in iron-overloaded hemodialysis patients. Kidney Int 36:1125-1132, 1989

191. Ward CG: Iron and infection: New developments and their implications. J Trauma 41:356-364, 1996

192. Weinberg ED: Iron withholding: A defense against infection and neoplasia. Physiol Rev 64:65-102, 1984 - No Abstract Available

193. Seifert A, Von Herrath D, Schaefer K: Iron overload, but not treatment with desferrioxamine favours the development of septecemia in patients on maintenance hemodialysis. Q J Med 65:1015-1024, 1987

194. Hoen B, Kessler M, Hestin D, Fondu P: Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicenter prospective survey. Nephrol Dial Transplant 10:377-381, 1995

195. Cantinieaux BF, Boelaert J, Hariga CF, Fondu P: Impaired neurophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. J Clin Lab Med 111:524-528, 1988

196. Flament J, Goldman M, Waterlot Y, Dupont E, Wybran J, Vanherweghem J-L: Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 25:227-230, 1986

197. Hershko C, Peto TEA, Weatherall DJ: Iron and infection. BMJ 296:660-664, 1988 - No Abstract Available

198. Hoen B, Paul-Dauphin A, Hestin D, Kessler M: EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1999

199. Waterlot Y, Cantinieaux BF, Harriga-Muller C, Maertelaere-Laurent E, Fondu P: Impaired phagocytic activity of neutrophils in patients receiving hemodialysis: The critical role of iron overload. BMJ 291:501A, 1985 (abstr)

200. Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG: Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 5:504-507, 1990

201. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663, 1998

202. Lazarus JM, Hakim RM, Newell J: Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. Am J Kidney Dis 16:101-108, 1990

203. Sunder-Plassmann G, Horl WH: Erythropoietin and iron. Clin Nephrol 47:141-157, 1997

204. Johnson CA, Rosowski E, Zimmerman SW: A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN. Adv Perit Dial 8:444-447, 1992

205. Piraio-Biroli G, Bothwell TH, Finch CA: Iron absorption. II. The absorption of radioiron administered with a standard meal in man. J Lab Clin Med 51:24-36, 1958

206. Rastogi SP, Padilla F, Boyd CM: Effect of aluminum oxide on iron absorption. Kidney Int 8:417, 1975 - No Abstract Available

207. Bothwell TH, Piraio-Biroli G, Finch CA: Iron absorption. I. Factors influencing absorption. J Lab Clin Med 51:24-36, 1958

208. Drug Topics: Rx Products, in Medical Economics Company (ed):1996 Red Book. Montvale, NJ, Medical Economics, 1996, pp 93-512

209. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL: Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76:1718-1722, 1990

210. Macdougall IC, Roberts DE, Coles GA, Williams JD: Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 20:99-113, 1991

211. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer H-H: The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 34:499-508, 1992

212. Albitar S, Meulders Q, Hammoud H, Soutif C, Bouvier P, Pollini J: Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 10:40-43, 1995

213. Salmonson T: Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin. Scand J Urol Nephrol Suppl 129:1-66, 1990

214. Barnas U, Walzinger U, Peer G, Graf H: Subcutaneous versus intravenous adminstration of human recombinant erythropoietin in patients on chronic hemodialysis. Nefrologia 10:116-120, 1990

215. Besarab A, Flaherty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E: Clinical pharmacology and economics of recombinant erythropoietin end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 3:1405-1416, 1992

216. Bommer J, Ritz E, Weinreich T, Bommer G, Ziegler T: Subcutaneous erythropoietin. Lancet 2:406 1988 - No Abstract Available

217. Bommer J, Barth HP, Zeier M, Mandelbaum A, Bommer G, Ritz E, Reichel H, Novack R: Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 88:136-143, 1991 - No Abstract Available

218. Bommer J, Samtleben W, Koch KM, Baldamus CA, Grutzmacher P, Scigalla P: Variations of recombinant human erythropoietin application in hemodialysis patients. Contrib Nephrol 76:149-158, 1989 - No Abstract Available

219. Boran M, Dalva I, Yazicioglu A, Cetin S: Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients. Nephron 63:113-114, 1993 - No Abstract Available

220. Bovy C, Dubois B, Popovic A, Saint-Remy A, Rorive G: Mode of administration of erythropoietin (rHu-Epo)–Does it matter? Nephrol Dial Transplant 10:1951-1952, 1995 (abstr)

221. Canaud B, Bennhold I, Delons S, Donnadieu P, Foret M, Franz H, Hoerl W, Koesters W, Kreusser W, That HT, Polito-Bouloux C, Mion C, Poisson D: What is the optimum frequency of administration of r-huepo for correcting anemia in hemodialysis patients? Dial Transplant 24:306-309, 1995

222. Castro MCM, Abensur H, Centenno JR, Romao JE, Marcondes M, Sabbaga E: Comparison between thrice-weekly intravenous and once-weekly subcutaneous administration of rHuEPO in hemodialysis patients. Dial Transplant 23:132-143, 1994

223. Eidemak I, Friedberg MO, Ladefoged SD, Lokkegaard H, Pedersen E, Skielboe M: Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Nephrol Dial Transplant 7:526-529, 1992

224. Granolleras C, Branger B, Deschodt G, Shaldon S, Nonnast-Daniel B, Pollok M: Daily self-administered subcutaneous erythropoietin: Benefits in haemodialysis patients. Contrib Nephrol 82:49-54, 1990 - No Abstract Available

225. Kaufmann J, Reda D: A comparison of subcutaneous (SC) and intravenous (IV) administration of recombinant human erythropoietin (rHuEPO) in hemodialysis (HD) patients. J Am Soc Nephrol 7:1450A, 1996 (abstr)

226. Lim VS, Kirchner PT, Fangman J, Richmond J, DeGowin RL: The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis 14:496-506, 1989

227. Macdougall IC, Roberts DE, Coles GA, Williams JD: Intraperitoneal erythropoietin. Lancet 1:1389 1989 - No Abstract Available

228. McMahon LP, Dawborn JK: Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. Am J Nephrol 10:404-408, 1990

229. Morsli R, Moriniere P, El Esper N, Boitte F, Woller M, Fournier A: Comparison of s.c. and i.v. RHuEpo in patients on chronic hemodialysis: Comparable correction of anaemia with lower doses because of greater bioavailability. Nephrol Dial Transplant 8:961A, 1993 (abstr)

230. Muirhead N, Churchill DN, Goldstein M, Nadler SP, Posen G, Wong C, Slaughter D, Laplante P: Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 12:303-310, 1992

231. Navarro JF, Teruel JL, Marcen R, Ortuno J: Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route. Scand J Urol Nephrol 26:331-340, 1995

232. Paganini EP, Eschbach JW, Lazarus JM, Van Stone JC, Gimenez LF, Graber SE, Egrie JC, Okamoto DM, Goodkin DA: Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis 26:331-340, 1995

233. Parker KP, Mitch WE, Stivelman JC, Macon EJ, Bailey JL, Sands JM: Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 8:288-293, 1997

234. Pelegri A, Roca R, Rodriguez JA, Fort J, Mayo A, Camps J: Valuation upon the route of administration or RHuEPO in hemodialysis patients (HP). Kidney Int 44:1430A, 1993 (abstr)

235. Schaller R, Sperschneider H, Thieler H, Dutz W, Hans S, Voigt D, Marx M, Engelmann J, Schoter KH, Scigalla P, Stein G: Differences in intravenous and subcutaneous application of recombinant human erythropoietin: A multicenter trial. Artif Organs 18:552-558, 1994

236. Steffensen G, Aunsholt NA, Ahlbom G: Comparative crossover study of intravenously and subcutaneously administered recombinant human erythropoietin in hemodialysis patients. Blood Purif 10:241-247, 1992

237. Stevens JM, Strong CA, Oliver DO, Winearls CG, Cotes PM: Subcutaneous erythropoietin and peritoneal dialysis (letter). Lancet 1:1388-1389, 1989 - No Abstract Available

238. Vidau P, Peral V, Tome R, Rodriguez C, Herrera J: Intravenous (i.v.) versus subcutaneous (s.c.) administration of erythropoietin (EPO) in hemodialysis (HD) patients. Kidney Int 46:571A, 1994 (abstr)

239. Virot JS, Janin G, Guillaumie J, Michel P, Dubot P, Chevet D, Rifle G: Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient? Am J Kidney Dis 28:400-408, 1996

240. Zehnder C, Blumberg A: Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: Comparison between intravenous and subcutaneous administration. Nephron 57:485-486, 1991 - No Abstract Available

241. Besarab A, Besarab FM, Miller D: Effects of dialysis factors and route of administration on response of hemodialysis patients to recombinant human erythropoietin. ASAIO Trans 37:M181-M182, 1991

242. Jensen JD, Madsen JK, Jensen LW: Comparison of dose requirement, serum erythropoietin, and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. Eur J Clin Pharmacol 50:171-177, 1996 Full Text

243. Mondal K, Dressler R, Levine SD, Lynn R: Comparison of the erythropoietic effects of subcutaneous and intravenous erythropoietin (EPO) in hemodialysis patients. Am J Kidney Dis 19:A9, 1992 (abstr)

244. Stockenhuber F, Loibl U, Gottsauner-Wolf M, Jahn C, Manker W, Meisl TF, Balcke P: Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 59:399-402, 1991

245. Taylor JE, Belch JJF, Fleming LW, Mactier RA, Henderson IS, Stewart WK: Erythropoietin response and route of administration. Clin Nephrol 41:297-302, 1994

246. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous versus intravenous administration of erythropoietin in hemodialysis patients. N Engl J Med 339:578-583, 1998 - Full Text

247. de Schoenmakere G, Lameire N, Dhondt A, Van Loo A, Van der Goten J, Duym P, Vanholder R: The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant 13:1770-1775, 1998 - Full Text

248. Uehlinger DE, Gotch FA, Sheiner LB: A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51:76-89, 1992

249. Scigalla P: Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. Contrib Nephrol 88:201-211, 1991 - No Abstract Available

250. St. Peter WL, Lewis MJ, Macres MG: Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of epogen in hemodialysis patients. Am J Kidney Dis 32:470-474, 1998

251. Bommer J, Kugel M, Schoeppe W, Brunkhorst R, Samtleben W, Bramsiepe P, Scigalla P: Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol 66:85-93, 1988 - No Abstract Available

252. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, Mattern W, Schreiber M, Swartz R, Van Stone J, Watson A, Zimmerman S: Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 5:1517-1529, 1995

253. Bennett WM: A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1:990-998, 1991

254. The US Recombinant Human Erythropoietin Predialysis Study Group: Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18:50-59, 1991

255. Muirhead N, Wong C: Erythropoietin for anemia in high-risk hemodialyzed patients: Comparison of IV and SC administration. J Am Soc Nephrol 1:404 1990

256. Petersen J, Kang MS, Yeh I: The site of injection affects erythropoietin levels during dialysis. ASAIO J 42:263-265, 1996

257. Bargman JM, Jones JE, Petro JM: The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. Perit Dial Int 12:369-372, 1992

258. Reddingius RE, Schroder CH, Koster AM, Monnens LAH: Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis. Eur J Pediatr 153:850-854, 1994

259. Muirhead N, Hodsman AB: Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. Nephrol Dial Transplant 5:232-234, 1990 - No Abstract Available

260. Piraino B, Johnston JR: The use of subcutaneous erythropoietin in CAPD patients. Clin Nephrol 33:200-202, 1990

261. Slingeneyer A, Faller B, Laroche B, Ehmer B, Mion C: Self-administered daily subcutaneous recombinant human erythropoietin: An open randomised dose-finding study in ESRD patients receiving peritoneal dialysis. Contrib Nephrol 88:159-168, 1991 - No Abstract Available

262. Macdougall IC, Coles GA, Williams JD: Inhibition of a response to r-HuEPO in the presence of infections or malignancy. Erythropoiesis 3:29-30, 1992

263. Sun CH, Ward HJ, Paul WL, Koyle MA, Yanagawa N, Lee DBN: Serum erythropoietin levels after renal transplantation. N Engl J Med 321:151-156, 1996

264. Brown JH, Lappin TRJ, Elder GE, Taylor TN, Bridges JM, McGeown MG: The initiation of erythropoiesis following renal transplantation. Nephrol Dial Transplant 4:1076-1079, 1996

265. Besarab A, Caro J, Jarrell BE, Francos G, Erslev AJ: Dynamics of erythropoiesis following renal transplantation. Kidney Int 32:526-536, 1987

266. Almond MK, Tailor D, Marsh FP, Raftery MJ, Cunningham J: Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. Nephrol Dial Transplant 9:270-273, 1994

267. Danielson B: R-HuEPO hyporesponsiveness–Who and why? Nephrol Dial Transplant 10:69-73, 1995

268. Drueke TB: R-HuEPO hyporesponsiveness–Who and why? Nephrol Dial Transplant 10:62-68, 1995 - No Abstract Available

269. Douglas SW, Adamson JW: The anemia of chronic disorders: Studies of marrow regulation and iron metabolism. Blood 45:55-65, 1975

270. Hymes LC, Hawthorne SM, Clowers BM: Impaired response to recombinant erythropoietin therapy in children with peritonitis. Dial Transplant 23:462-463, 1994

271. Barany P, Divino Filho JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29:565-568, 1997

272. Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33:63-72, 1999

273. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171-175, 1993 - Full Text

274. Grutzmacher P, Ehmer B, Limbach J, Messinger D, Kulbe KD, Scigalla P: Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism. Blood Purif 8:279-284, 1990

275. Steffen HM, Brunner R, Muller R, Degenhardt S, Pollok M, Lang R, Baldamus CA: Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 76:292-298, 1989

276. Rosenlof K, Fyhrquist F, Tenhunen R: Erythropoietin aluminum and anemia in patients on hemodialysis. Lancet 335:247-249, 1990

277. Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE: The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 6:342-345, 1991

278. Grutzmacher P, Ehmer B, Messinger D, Kulbe KD, Scigalla P: Effect of aluminum overload on the bone marrow response to recombinant human erythropoietin. Contrib Nephrol 76:315-323, 1989 - No Abstract Available

279. Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. BMJ 295:1017-1020, 1987

280. Tomson CR, Edmunds ME, Chambers K, Bricknell S, Feehally J, Walls J: Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 7:817-821, 1992

281. Steinberg MH: Erythropoietin for anemia of renal failure in sickle cell disease (letter). N Engl J Med 324:1369-1370, 1991 - No Abstract Available

282. Roger SE, Macdougall IC, Thuraisingham RC, Raine AEG: Erythropoietin in anemia of renal failure in sickle cell disease (letter). N Engl J Med 325:1175-1176, 1991 - No Abstract Available

283. Cheng IKP, Lu H, Wei DCC, Cheng S, Chan C, Lee FCP: Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol 13:142-148, 1993

284. Lai KN, Wong KC, Li PKT, Lui SF: Use of recombinant erythropoietin in thalassemic patients on dialysis. Am J Kidney Dis 19:239-245, 1992

285. Drinovec J, Varl J: Subcutaneous erythropoietin in the treatment of renal anaemia. Przegl Lek 49:38-40, 1992

286. Ono K, Hisasue Y: Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy? Clin Nephrol 38:290-292, 1992

287. Zachee P, Chew SL, Daelemans R, Lins RL: Erythropoietin resistance due to vitamin B12 deficiency: Case report and retrospective analysis of B12 levels after erythropoietin treatment. Am J Nephrol 12:188-191, 1992

288. Klemm A, Sperschneider H, Lauterbach H, Stein G: Is folate and vitamin B12 supplementation necessary in chronic hemodialysis patients with EPO treatment? (letter) Clin Nephrol 42:343-345, 1994 - No Abstract Available

289. Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F: Folic acid supplementation improves erythropoietin response. Nephron 71:395-400, 1995

290. Caillette A, Barreto S, Gimenez E, Labeeuw M, Zech P: Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis? Clin Nephrol 40:176-178, 1993

291. Taylor JK, Mactier RA, Stewart WK, Henderson IS: Effect of erythropoietin on anaemia in patients with myeloma receiving hemodialysis. BMJ 301:476-477, 1990 - No Abstract Available

292. Ruedin P, Pechere Bertschi A, Chapuis B, Benedet P, Leski M: Safety and efficacy of recombinant human erythropoietin treatment of anaemia associated with multiple myeloma in haemodialysed patients. Nephrol Dial Transplant 8:315-318, 1993

293. Roger S, Russell NH, Morgan AG: Effect of erythropoietin in patients with myeloma. BMJ 301:667, 1990 - No Abstract Available

294. Madour F, Bridges K, Brugnara NL, Lew EG, Lowrie EG, Lazarus JM, Owen WF: A population study of the interplay between iron, nutrition, and inflammation in erythropoiesis in hemodialysis patients. J Am Soc Nephrol 7:1456A, 1996 (abstr)

295. Siimes MA, Ronnholm KAR, Antikainen M, Holmberg C: Factors limiting the erythropoietin response in rapidly growing infants with congenital nephrosis on a peritoneal dialysis regimen after nephrectomy. J Pediatr 120:44-48, 1992

296. Evers J: Cardiac hemolysis and anemia refractory to erythropoietin: On anemia in dialysis patients (letter). Nephron 71:108, 1995 - No Abstract Available

297. Onoyama K, Sanai T, Motomura K, Fujishima M: Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol 13:S27-S30, 1989

298. Sanchez JA: ACE inhibitors do not decrease rHuEPO response in patients with end-stage renal failure (letter). Nephrol Dial Transplant 10:1476-1477, 1995 - No Abstract Available

299. Conlon PJ, Albers F, Butterly D, Schwab S: ACE inhibitors do not affect erythropoeitin efficiency in hemodialysis patients (letter). Nephrol Dial Transplant 9:1359-1360, 1994 - No Abstract Available

300. Abu-Alfa AK, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ: ACE inhibitors do not induce recombinant human erythropoeitin resistance in hemodialysis patients. Am J Kidney Dis 35:1076-1082, 2000

301. Hess E, Sperschhneider H, Stein G: Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? (letter) Nephrol Dial Transplant 11:749-751, 1997

302. Walter J: Does catopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? (letter) Nephrol Dial Transplant 8:142, 1993 - No Abstract Available

303. Dhondt AW, Vanholder RC, Ringoir SMG: Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant 10:2107-2109, 1995 - No Abstract Available

304. Erturk S, Ates K, Durman N, Karatan O, Erbay B, Ertug E: Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: Possible implications of angiotensin converting enzyme inhibitors. Nephrol Dial Transplant 11:393-397, 1996 - No Abstract Available

305. Albitar S, Genin R, Fen-Chong M, Serveaux M-O, Bourgeon B: High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 13:1206-1210, 1998 - Full Text

306. Kooistra MP, Struyvenberg A, van Es A: The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels (letter). Nephron 57:127-128, 1991 - No Abstract Available

307. Berard E, Barrillon D, Iordache A, Bayle J, Cassuto-Viguler E: Low dose of L-carnitine impairs membrane fragility of erythrocytes in hemodialysis patients (letter). Nephron 68:145, 1994- No Abstract Available

308. Berard E, Iordache A: Effects of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: About two cases. Nephron 62:368-369, 1992 - No Abstract Available

309. Labonia WD: L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 26:757-764, 1995

310. Kletzmayr J, Mayer G, Legenstein E, Heinz-Peer G, Leitha T, Hori WH, Kovarik J: Anemia and carnitine supplementation in hemodialysis patients. Kidney Int 55:S93-S106, 1999 (suppl 69)

311. Berns JS, Rudnick MR, Cohen RM: A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 37:264-267, 1992

312. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ: Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 17:29-33, 1991

313. Teruel JL, Marcen R, Navarro-Antolin J, Aguilera A, Fernandez G, Ortuno J: Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: A prospective study. J Am Soc Nephrol 7:140-144, 1996

314. Paganini EP, Abdulhadi MH, Garcia J, Magnusson MO: Recombinant human erythropoietin correction of anemia: Dialysis efficiency, waste retention, and chronic dose variables. ASAIO Trans 35:513-515, 1989

315. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334:420-425, 1996 - Full Text

316. Eschbach JW: EPO treatment in dialysis. Which hematocrit target? Does dialysis quality influence dose? International Congress of Nephrology, Madrid, Spain, July 1995, p 90 (abstr)

317. Charra B, Calemard E, Ruffet M, Chazot C, Terrat J-C, Vanel T, Laurent G: Survival as an index of adequacy in dialysis. Kidney Int 41:1286-1291, 1992

318. Audet AM, Goodnough LT: Practice strategies for elective red blood transfusion. Ann Intern Med 116:403-406, 1992 - No Abstract Available

319. Haedersdal C, Mehlsen J, Stenver D, Nielsen B, Jeppesen L, Winther K: Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure. Angiology 45:231-234, 1994

320. Nomoto Y, Kawaguchi Y, Kubota M, Tagawa H, Kubo K, Ogura Y, Shoji T, Kawada Y, Koshikawa S, Mimura N, Maeda T: A multicenter study with once a week or once every two weeks high-dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. Perit Dial Int 14:56-60, 1994

321. Pais MJ, Gaspar A, Santana A, Bruges M, Simoes J: Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Perit Dial Int 13:S541-S543, 1993

322. Buccianti G, Colombi L, Battistel V: Use of recombinant human erythropoietin (rh-EPO) in the treatment of anemia in hemodialysis patients: A multicenter Italian experience. Haematologica 78:111-117, 1993

323. Barany P, Pettersson E, Konarski-Svensson JK: Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant 8:426-432, 1993

324. Roger SD, Baker LRI, Raine AEG: Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO). Clin Nephrol 39:103-110, 1993

325. Stefanidis CJ, Koulieri A, Siapera D, Kapogiannis A, Mitsioni A, Michelis K: Effect of the correction of anemia with recombinant human erythropoietin on growth of children treated with CAPD. Adv Perit Dial 8, 460-463, 1992

326. Frenken LAM, Struijk DG, Coppens PJW, Tiggeler RGWL, Krediet RT, Koene RAP: Intraperitoneal administration of recombinant human erythropoietin. Perit Dial Int 12:378-383, 1992

327. Pascual J, Teruel JL, Marcen R, Liano F, Ortuno J: Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs 15:393-396, 1992

328. Piazza V, Villa G, Galli F, Segagni S, Bovio G, Poggio F, Picardi L, Bianco L, Salvadeo A, Barosi G: Erythropoietin as treatment of haemodialysis-related porphyria cutanea tarda. Nephrol Dial Transplant 7:438-442, 1992 - No Abstract Available

329. Stevens ME, Summerfield GP, Hall AA, Beck CA, Harding AJ, Cove-Smith JR, Paterson AD: Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. BMJ 304:474-477, 1992

330. Takayama K, Nagai T, Kinugasa E, Akizawa T, Koshikawa S: Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients. ASAIO Trans 37:M183-M188, 1991

331. Bianchetti MG, Hammerli I, Roduit C, Neuhaus TJ, Leumann EP, Oetliker OH: Epoetin alfa in anaemic children or adolescents on regular dialysis. Eur J Pediatr 150:509-512, 1991

332. Bajo MA, Selgas R, Miranda B, Fernandez-Zamorano A, Borrego F, Romero JR, Caparros G, Rinon C, Sanchez Sicilia L: Medium term response to H-R erythropoietin in CAPD patients: The influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity. Adv Perit Dial 7:296-300, 1991

333. Saleh A, Krane NK, Caballero M, Starks E: Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD. Adv Perit Dial 7:288-291, 1991

334. Lye WC, Lee EJC: Subcutaneous recombinant human erythropoietin in patients on CAPD. Adv Perit Dial 7:285-287, 1991

335. Tsai JC, Lai YH, Tsai ZY, Chien LJ, Tsai JH: Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: Influence of dosing regimen, iron status, and serum aluminum. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 7:126-135, 1991

336. Ramirez B, Flores A, Perez F, Cordoba C, Garcia L, Vazquez G: Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CKD): Experience with a group of patients on chronic haemodialysis treatment. Transplant Proc 23:1833-1834, 1991 - No Abstract Available

337. Canadian Erythropoietin Study Group: Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol 11:23-26, 1991

338. Lai KN, Lui SF, Leung JCK, Law E, Nicholls MG: Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 57:394-400, 1991

339. Lubrich-Birkner I, Schollmeyer P, Steinhauer HB: One year experience with subcutaneous human erythropoietin in CAPD: Correction of renal anemia and increased ultrafiltration. Adv Perit Dial 6:302-307, 1990

340. Barany P, Pettersson E, Bergstrom J: Erythropoietin treatment improves quality of life in hemodialysis patients. Scand J Urol Nephrol Suppl 131:55-60, 1990

341. Offner G, Hoyer PF, Latta K, Winkler L, Brodehl J, Scigalla P: One year’s experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis. Pediatr Nephrol 4:498-500, 1990

342. Edmunds ME, Walls J, Tucker B, Baker LRI, Tomson CRV, Ward M, Cunningham J, Moore R, Winearls CG: Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 4:1065-1069, 1989

343. Onoyama K, Kumagai H, Takeda K, Shimamatsu K, Fujishima M: Effects of human recombinant erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients. Nephrol Dial Transplant 4:966-970, 1989

344. Steinhauer HB: Effects of long-term treatment with human recombinant erythropoietin in patients on CAPD. Adv Exp Med Biol 157-165, 1989 - No Abstract Available

345. Lui SF, Chung WWM, Leung CB, Chan K, Lai KN: Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 33:47-51, 1990

346. Vaziri ND, Ritchie C, Brown P, Kaupke J, Atkins K, Barker S, Hyatt J: Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients. ASAIO Trans 35:505-508, 1989

347. Pollok M, Bommer J, Gurland HJ, Koch KM, Schoeppe W, Scigalla P, Baldamus CA: Effects of recombinant human erythropoietin treatment in end-stage renal failure patients: Results of a multicenter phase II/III study. Contrib Nephrol 76:201-211, 1989 - No Abstract Available

348. Samtleben W, Baldamus CA, Bommer J, Grutzmacher P, Nonnast-Daniel B, Scigalla P, Gurland HJ: Indications and contraindications for recombinant human erythropoietin treatment: Results in hemodialysis patients. Contrib Nephrol 76:193-200, 1989 - No Abstract Available

349. Suzuki M, Hirasawa Y, Hirashima K, Arakawa M, Odaka M, Ogura Y, Yoshikawa Y, Sanaka T, Shinoda A, Morii H: Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Contrib Nephrol 76:179-192, 1989 - No Abstract Available

350. Nielsen OJ, Thaysen JH: Response to erythropoietin in anaemic haemodialysis patients. J Intern Med 226:89-94, 1989

351. Verbeelen D, Hauglustaine D, Sennesael J: Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin. Neth J Med 33:60-67, 1988 - No Abstract Available

352. Drueke T, Zins B, Naret C, Casadevall N, Goureau Y, Bererhi L, Peterlongo F, Castaigne JP, Zingraff J, Delons S, Kreis H, Varet B: Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure. Adv Nephrol Necker Hosp 18:187-206, 1989

353. Zehnder C, Gluck Z, Descoeudres C, Uehlinger DE, Blumberg A: Human recombinant erythropoietin in anaemic patients on maintenance haemodialysis: Secondary effects of the increase of haemoglobin. Nephrol Dial Transplant 3:657-660, 1988

354. Bommer J, Alexiou C, Muller-Buhl U, Eifert J, Ritz E: Recombinant human erythropoietin therapy in haemodialysis patients: Dose determination and clinical experience. Nephrol Dial Transplant 2:238-242, 1987

355. Faller B, Slingeneyer A, Waller M, Michel C, Grutzmacher P, Muller HP, Barany P, Grabensee B, Issad B, Schmitt H, Meisl F: Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: A European dose-response study. Clin Nephrol 40:168-175, 1993

356. Eschbach JW, Davidson RC: Red blood cell mass/erythropoietin and blood pressure: Lessons from patients with renal disease, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management (ed 2). New York, NY, Raven Press, Ltd, 1995, pp 389-398

357. Angnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT: Erthropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 91:3974-3978, 1994 - Full Text

358. Akimoto T, Kusano E, Inaba T, Limura O, Takahashi H, Ikeda H, Ito C, Ando Y, Ozawa K, Asano Y: Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 58:269-282, 2000 - Full Text

359. Banerjee D, Rodriguez M, Nag M, Adamson JW: Exposure of endothelial cells to recombinant human erythropoeitin induces nitric oxide synthase activity. Kidney Int 57:1895-1904, 2000 - Full Text

360. Kang D, Yoon K, Han D: Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol Dial Transplant 13:2877-2883, 1998 - Full Text

361. Ni Z, Wang XQ, Vaziri ND: Nitric oxide metabolism in erythropoietin-induced hypertension: Effect of calcium channel blockade. Hypertension 32:724-729, 1998 - Full Text

362. Duff DR, Golper TA, Sloan RS, Brier ME, Aronoff GR: Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. Am J Kidney Dis 18:60-64, 1991

363. Johnson WJ, McCarthy JT, Yanagihara T, Osmundson PJ, Ilstrup DM, Jenson BM, Bowie EJW: Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. Kidney Int 38:919-924, 1990

364. Laupacis A: Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. Semin Nephrol 10:11-19, 1990 - No Abstract Available

365. Krantz SB: Review of patients’ responses to epoetin alfa therapy. Pharmacotherapy 10:15S-21S, 1990

366. Fischer-Colbrie W, Clyne N, Jogestrand T, Takolander R: The effect of erythropoietin treatment on arteriovenous haemodialysis fistula/graft: A prospective study with colour flow Doppler ultrasonography. Eur J Vasc Surg 8:346-350, 1994

367. Shand BI, Buttimore AL, Hurrell MA, Wells JE, Inkster JA, Bailey RR, Robson RA, Lynn KL: Hemorheology and fistula function in home hemodialysis patients following erythropoietin treatment: A prospective placebo-controlled study. Nephron 64:53-57, 1993

368. Eschbach JW, Aquiling T, Haley NR, Fan MH, Blagg CR: The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 38:S98-S103, 1992

369. Wirtz JJJM, van Esser JWJ, Hamulyak K, Leunissen KML, van Hooff JP: The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients. Clin Nephrol 38:277-282, 1992

370. Bahlmann J, Schoter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, Muthny FA, Neumayer HH, Pommer W, Quellhorst E, Sieberth HG, Weber U: Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: A controlled study. Contrib Nephrol 88:90-106, 1991 - No Abstract Available

371. Samtleben W, Ehmer B, Lutz-Knochenhauer I, Hagmann C, Scigalla P, Gurland HJ: Side effects during recombinant human erythropoietin therapy in 2,000 ESRD patients. Contrib Nephrol 88:107-116, 1991 - No Abstract Available

372. Fabris F, Cordiano I, Randi ML, Casonato A, Montini G, Zacchello G, Girolami A: Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis. Pediatr Nephrol 5:225-228, 1991

373. Delano BG, Lundin AP, Galonsky R, Quinn-Cefaro RM, Rao TKS, Friedman EA: Dialyzer urea and creatinine clearances are not significantly altered in erythropoietin treated maintenance hemodialysis patients. ASAIO Trans 36:36-39, 1990

374. Canaud B, Polito-Bouloux C, Garred LJ, Rivory JP, Donnadieu P, Taib J, Florence P, Mion C: Recombinant human erythropoietin: 18 months’ experience in hemodialysis patients. Am J Kidney Dis 15:169-175, 1990

375. Schaefer RM, Kuerner B, Zech M, Denninger G, Borneff C, Heidland A: Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin. Int J Artif Organs 11:249-254, 1988

376. Klinkmann H, Wieczorek L, Scigalla P: Adverse events of subcutaneous recombinant human erythropoietin therapy: Results of a controlled multicenter European study. Artif Organs 17:219-225, 1993

377. de Marchis, Cecchin E, Falleti E, Giacomello R, Stel G, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E: Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 8:1147-1156, 1997

378. Muirhead N: Erythropoietin is a cause of access thrombosis. Semin Dial 6:184-188, 1993

379. Wiesholzer M, Kitzwogerer M, Harm F, Barbieri G, Hauser A-C, Pribasnig A, Bankl H, Balcke P: Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin. Am J Kidney Dis 33:702-708, 1999

380. Wakeen M, Zimmerman SW: Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 32:488-493, 1998

381. Von Kummer R, Scharf J, Back T, Reich H, Machens HG, Wildemann B: Auto regulatory capacity and the effect of isovolemic hemodilution on local cerebral blood. Stroke 23:594-597, 1988

382. Hino A, Ueda S, Mizukawa N, Imahori Y, Tenjin H: Effects of hemodilution on cerebral hemodynamics and oxygen metabolism. Stroke 23:423-426, 1992

383. Evans SJW: Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients (letter). Nephron 76:116, 1997 - No Abstract Available

384. Iseki K: Reply to the letter by S.J.W. Evans. Nephron 76:117, 1997

385. Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K: Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 44:1086-1090, 1993

386. Longnnecker RE, Goffinet JA, Hendler ED: Blood loss during maintenance hemodialysis. Trans Am Soc Artif Intern Organs 20:135-141, 1974 - No Abstract Available

387. Lindsay RM, Burton JA, Edward N, Dargie HJ, Prentice CRM, Kennedy AC: Dialyzer blood loss. Clin Nephrol 1:29-34, 1973 - No Abstract Available

388. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716, 1989

389. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soelder JS, Bunn HF: Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304:319-325, 1981

390. Okuno Y, Takahashi T, Suzuki A, Ichiba S, Nakamura K, Hitomi K, Sasaki R, Imura H: Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 170:1128-1134, 1990

391. Dessypris E, Graber SE, Krantz SB, Stone WJ: Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 72:2060-2062, 1988

392. Geissler K, Stockenhuber F, Kabrina E, Hinterberger W, Balke P, Lechner K: Recombinant human erythropoietin and hematopoietic progenitor cells in vivo (letter). Blood 73:2229, 1989 - No Abstract Available

393. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor DW: Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 4:1809-1813, 1994

 

 

© 2001 National Kidney Foundation, Inc

web version created by cyberNephrologyTM and The Nephron Information Center